

ExonHit's combined ordinary and extraordinary annual shareholders' meeting

- Shareholders approved all of the ordinary meeting resolutions proposed by the Management Board
- A meeting will be held, on second notice, to vote on extraordinary resolutions

Paris, France – April 27, 2011 – At the shareholders' meeting held today with a quorum of 23.17%, ExonHit's shareholders approved all ordinary meeting resolutions proposed by the Management Board.

Specifically, shareholders approved:

- both the statutory and consolidated financial accounts for 2010;
- Patrick Langlois and Frédéric Desdouts reelection as members of the Supervisory Board;
- the global amount of directors fees for distribution among Supervisory Board members;
- the authorization to the Management Board to set up a share buyback program as part of a liquidity agreement. ExonHit hired Natixis to implement such a liquidity agreement in order to encourage trading liquidity for the benefit of Company's shareholders. Natixis acts independently of ExonHit, according to good business practice as required by French financial market regulations.

An extraordinary shareholders' meeting will be convened and held, on second notice, Wednesday, May 18, 2011, at 10:00 am CET, at Company's headquarters in Paris (63-65 Bd Masséna, 75013 Paris).

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast emerging healthcare player active in both therapeutics and diagnostics. The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative molecular diagnostic tests and therapeutics for Alzheimer's disease and cancer indications. ExonHit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with Allergan.

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris and is part of the NYSE Alternext OSEO innovation index. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

Contact for Media & Investors

Corinne Hoff

+33 1 58 05 47 04

corinne.hoff@exonhit.com